Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company specializing in neurohealth disorders, has announced the granting of inducement awards to sixteen new non-executive employees. The awards consist of Restricted Stock Units (RSUs) representing a total of 55,200 shares of the Company's common stock.
These inducement awards were approved by Neuronetics' Compensation Committee in compliance with NASDAQ Listing Rule 5635(c)(4). The RSUs will vest in equal installments over four years, with vesting occurring on the first, second, third, and fourth anniversaries of the grant date. Vesting is contingent upon the recipient's continued employment with the Company. The RSUs are subject to the terms of the Neuronetics 2020 Inducement Plan.
Neuronetics, Inc. (NASDAQ: STIM), un'azienda tecnologica medica in fase commerciale specializzata in disturbi neuro della salute, ha annunciato l'assegnazione di premi di incentivazione a sedici nuovi dipendenti non esecutivi. I premi consistono in Unità di Azioni Riservate (RSU) che rappresentano un totale di 55.200 azioni in circolazione della Società.
Questi premi di incentivazione sono stati approvati dal Comitato per la Compensazione di Neuronetics in conformità con la Regola di quotazione NASDAQ 5635(c)(4). Le RSU matureranno in rate uguali nel corso di quattro anni, con la maturazione che avverrà nei primi, secondi, terzi e quarti anniversari della data di concessione. La maturazione è subordinata al continuo impiego del destinatario presso la Società. Le RSU sono soggette ai termini del Piano di Incentivazione 2020 di Neuronetics.
Neuronetics, Inc. (NASDAQ: STIM), una empresa de tecnología médica en fase comercial especializada en trastornos de neuro-salud, ha anunciado la concesión de premios de incentivo a dieciséis nuevos empleados no ejecutivos. Los premios consisten en Unidades de Acciones Restringidas (RSU) que representan un total de 55,200 acciones ordinarias de la Compañía.
Estos premios de incentivo fueron aprobados por el Comité de Compensación de Neuronetics de acuerdo con la Regla de Cotización 5635(c)(4) de NASDAQ. Las RSU se concederán en partes iguales durante cuatro años, con la concesión ocurriendo en el primer, segundo, tercero y cuarto aniversario de la fecha de otorgamiento. La concesión está sujeta a la continuación del empleo del beneficiario en la Compañía. Las RSU están sujetas a los términos del Plan de Incentivo 2020 de Neuronetics.
Neuronetics, Inc. (NASDAQ: STIM)는 신경 건강 장애를 전문으로 하는 상업 단계의 의료 기술 회사로, 16명의 신규 비상근 직원에게 유인 보상을 부여했다고 발표했습니다. 이 보상은 회사의 보통주 총 55,200주에 해당하는 제한주식유닛(RSU)으로 구성되어 있습니다.
이 유인 보상은 NASDAQ 상장 규칙 5635(c)(4)에 따라 Neuronetics 보상위원회의 승인을 받았습니다. RSU는 4년 동안 동등한 할부로 불입되며, 부여일의 첫 번째, 두 번째, 세 번째 및 네 번째 기념일에 불입됩니다. 불입은 수혜자가 회사에 계속 고용되어 있는 것을 전제로 합니다. RSU는 Neuronetics 2020 유인 계획의 조건에 따라 적용됩니다.
Neuronetics, Inc. (NASDAQ: STIM), une entreprise de technologie médicale en phase commerciale spécialisée dans les troubles de la neuro-santé, a annoncé l'octroi de récompenses d'incitation à seize nouveaux employés non-exécutifs. Les récompenses consistent en des unités d'actions restreintes (RSU) représentant un total de 55 200 actions ordinaires de la société.
Ces récompenses d'incitation ont été approuvées par le comité de rémunération de Neuronetics conformément à la règle de cotation NASDAQ 5635(c)(4). Les RSU seront acquises par tranches égales sur quatre ans, avec des acquisitions pouvant se produire aux premier, deuxième, troisième et quatrième anniversaires de la date d'octroi. L'acquisition dépend de l'emploi continu du bénéficiaire auprès de la société. Les RSU sont soumises aux conditions du plan d'incitation 2020 de Neuronetics.
Neuronetics, Inc. (NASDAQ: STIM), ein Unternehmen für medizinische Technologie in der kommerziellen Phase, das sich auf neurogesundheitliche Störungen spezialisiert hat, hat die Gewährung von Anreizprämien an sechzehn neue nicht-executive Mitarbeiter bekannt gegeben. Die Prämien bestehen aus eingeschränkten Aktieneinheiten (RSUs), die insgesamt 55.200 Aktien des Unternehmens entfalten.
Diese Anreizprämien wurden vom Vergütungsausschuss von Neuronetics gemäß der NASDAQ-Börsenregel 5635(c)(4) genehmigt. Die RSUs werden über einen Zeitraum von vier Jahren in gleichen Raten fällig, wobei die Fälligkeit an den ersten, zweiten, dritten und vierten Jahrestagen des Zuschlagsdatums erfolgt. Die Fälligkeit setzt die fortdauernde Beschäftigung des Empfängers im Unternehmen voraus. Die RSUs unterliegen den Bedingungen des Neuronetics 2020 Anreizplans.
- Granting of RSUs may help attract and retain talented employees
- Compliance with NASDAQ Listing Rule 5635(c)(4) demonstrates good corporate governance
- Potential dilution of existing shareholders' ownership due to the issuance of 55,200 new shares
MALVERN, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 55,200 shares of the Company’s common stock (RSUs) to sixteen new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as material inducements to their respective employment with the Company.
Each of the RSU grants vests ratably in equal installments on the first, second, third and fourth anniversaries of the grant date, subject to the recipient’s continued service with the Company through the applicable vesting date. The RSUs are subject to the terms of the Neuronetics 2020 Inducement Plan.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience and the largest TMS company in the industry, Neuronetics is redefining patient and physician expectations by designing and developing products that improve the quality of life for people suffering from psychiatric disorders. An FDA-cleared, non-drug, noninvasive treatment for people with depression, Neuronetics’ NeuroStar® Advanced Therapy system is today’s leading transcranial magnetic stimulation (TMS) treatment for major depressive disorder with over 4.8 million treatments delivered. NeuroStar is widely researched and backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Our NeuroStar® Advanced Therapy system is also FDA-cleared to treat people suffering from obsessive-compulsive disorder, as well as for the treatment of comorbid anxiety symptoms (“anxious depression”) for adults with MDD suffering from anxiety symptoms. Neuronetics is committed to transforming lives by offering an exceptional treatment option that produces extraordinary results. For safety information and indications for use, visit NeuroStar.com.
“Safe harbor” statement under the Private Securities Litigation Reform Act of 1995:
Statements in the press release regarding Neuronetics, Inc. (the “Company”) that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “outlook,” “potential,” “believe,” “expect,” “plan,” “anticipate,” “predict,” “may,” “will,” “could,” “would” and “should” as well as the negative of these terms and similar expressions. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to: the impact of COVID-19 on the Company’s operational and budget plans as well as general political and economic conditions, including as a result of efforts by governmental authorities to mitigate COVID-19, such as travel bans, shelter in place orders and third-party business closures and the related impact on resource allocations, manufacturing and supply chains and patient access to commercial products; the Company’s ability to execute its business continuity; the Company’s ability to achieve or sustain profitable operations due to its history of losses; the Company’s reliance on the sale and usage of its NeuroStar Advanced Therapy for Mental Health System to generate revenues; the scale and efficacy of the Company’s salesforce as well as the Company’s ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using the Company’s products; physician and patient demand for treatments using the Company’s products; developments in respect of competing technologies and therapies for the indications that the Company’s products treat; product defects; the Company’s ability to obtain and maintain intellectual property protection for its technology; developments in clinical trials or regulatory review of NeuroStar Advanced Therapy for Mental Health System for additional indications; and developments in regulation in the United States and other applicable jurisdictions. For a discussion of these and other related risks, please refer to the Company’s recent SEC filings which are available on the SEC’s website at www.sec.gov. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or changes in the Company’s expectations.
Investor Contact:
Mike Vallie or Mark Klausner
ICR Westwicke
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
FAQ
How many shares of Neuronetics (STIM) were granted as inducement awards?
What is the vesting schedule for the RSUs granted by Neuronetics (STIM)?
How many new employees received inducement awards from Neuronetics (STIM)?
Under which plan are the RSUs granted by Neuronetics (STIM) subject to?
